SET complex in serous epithelial ovarian cancer

International Journal of Cancer

Volumn 119, Issue 9, 2006, Pages 2119-2126

  Ouellet, Véronique ^a   Page, Cécile Le ^a   Guyot, Marie Claude ^a   Lussier, Christian ^a   Tonin, Patricia N ^b,c   Provencher, Diane M ^a,d   Mes Masson, Anne Marie ^a,d  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Diagnostic and prognositic markers; Immunohistochemistry; Low malignant potential borderline tumors; Serous epithelial ovarian cancer; SET complex

Indexed keywords

APE1 PROTEIN; HIGH MOBILITY GROUP B2 PROTEIN; NM23 PROTEIN; PP32 PROTEIN; PROTEIN DERIVATIVE; SET PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CHRONIC DISEASE; COMPLEX FORMATION; DISEASE MARKER; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; NOMOGRAM; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEROUS EPITHELIAL OVARIAN CANCER; TISSUE MICROARRAY;

ADULT; AGED; CARCINOMA; CHROMOSOMAL PROTEINS, NON-HISTONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS;

EID: 33748858099     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22054     Document Type: Article

References (67)

1. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
2. Tavassoli FA. Serous tumor of low malignant potential with early stromal invasion (serous LMP with microinvasion). Mod Pathol 1988;1:407-14.
3. Burger CW, Prinssen HM, Baak JP, Wagenaar N, Kenemans P. The management of borderline epithelial tumors of the ovary. Int J Gynecol Cancer 2000;10:181-97.
4. Dietel M, Hauptmann S. Serous tumors of low malignant potential of the ovary. 1. Diagnostic pathology. Virchows Arch 2000;436:403-12.
5. de Souza PL, Friedlander ML. Prognostic factors in ovarian cancer. Hematol Oncol Clin North Am 1992;6:761-82.
6. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S. Carcinoma of the ovary. Int J Gynaecol Obstet 2003;83 (Suppl 1):135-66.
7. Ouellet V, Provencher DM, Maugard CM, Page CL, Ren F, Lussier C, Novak J, Ge B, Hudson TJ, Tonin PN, Mes-Masson AM. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005;24:4672-87.
8. Lieberman J, Fan Z. Nuclear war: the granzyme A-bomb. Curr Opin Immunol 2003;15:553-9.
9. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 2003;112:659-72.
10. Nakamura J, Swenberg JA. Endogenous apurinic/apyrimidinic sites in genomic DNA of mammalian tissues. Cancer Res 1999;59:2522-6.
11. Bennett RA, Wilson DM, III, Wong D, Demple B. Interaction of human apurinic endonuclease and DNA polymerase β in the base excision repair pathway. Proc Natl Acad Sci USA 1997;94:7166-9.
12. Fan Z, Beresford PJ, Zhang D, Xu Z, Novina CD, Yoshida A, Pommier Y, Lieberman J. Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nat Immunol 2003;4:145-53.
13. Ouellet V, Guyot M-C, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher D, Mes-Masson AM. Tissue array validation of microarray candidates identifies new molecular markers that correlated with tumor grade and outcomes in serous epithelial ovarian cancer. Int J Cancer 2006;119:599-607.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
15. Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 2001;104:119-30.
16. Shikama N, Chan HM, Krstic-Demonacos M, Smith L, Lee CW, Cairns W, La Thangue NB. Functional interaction between nucleosome assembly proteins and p300/CREB-binding protein family coactivators. Mol Cell Biol 2000;20:8933-43.
17. Cervoni N, Detich N, Seo SB, Chakravarti D, Szyf M. The oncoprotein Set/TAF-1β, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J Biol Chem 2002;277:25026-31.
18. Seo SB, Macfarlan T, McNamara P, Hong R, Mukai Y, Heo S, Chakravarti D. Regulation of histone acetylation and transcription by nuclear protein pp32, a subunit of the INHAT complex. J Biol Chem 2002;277:14005-10.
19. Kimura N, Shimada N, Fukuda M, Ishijima Y, Miyazaki H, Ishii A, Takagi Y, Ishikawa N. Regulation of cellular functions by nucleoside diphosphate kinases in mammals. J Bioenerg Biomembr 2000;32:309-15.
20. Roymans D, Willems R, Van Blockstaele DR, Slegers H. Nucleoside diphosphate kinase (NDPK/NM23) and the waltz with multiple partners: possible consequences in tumor metastasis. Clin Exp Metastasis 2002;19:465-76.
21. Caligo MA, Cipollini G, Fiore L, Calvo S, Basolo F, Collecchi P, Ciardiello F, Pepe S, Petrini M, Bevilacqua G. NM23 gene expression correlates with cell growth rate and S-phase. Int J Cancer 1995;60:837-42.
22. Halperin R, Zehavi S, Dar P, Habler L, Hadas E, Bukovsky I, Schneider D. Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas. Eur J Gynaecol Oncol 2001;22:292-6.
23. Kitakata H, Nemoto-Sasaki Y, Takahashi Y, Kondo T, Mai M, Mukaida N. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res 2002;62:6682-7.
24. Leone A, Flatow U, VanHoutte K, Steeg PS. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity. Oncogene 1993;8:2325-33.
25. Leone A, Flatow U, King CR, Sandeen MA, Margulies IM, Liotta LA, Steeg PS. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 1991;65:25-35.
26. Suzuki E, Ota T, Tsukuda K, Okita A, Matsuoka K, Murakami M, Doihara H, Shimizu N. nm23-H1 reduces in vitro cell migration and the liver metastatic potential of colon cancer cells by regulating myosin light chain phosphorylation. Int J Cancer 2004;108:207-11.
27. Hartsough MT, Steeg PS. Nm23/nucleoside diphosphate kinase in human cancers. J Bioenerg Biomembr 2000;32:301-8.
28. Lombards D, Lacombe ML, Paggi MG. nm23: unraveling its biological function in cell differentiation. J Cell Physiol 2000;182:144-9.
29. Hailat N, Keim DR, Melhem RF, Zhu XX, Eckerskorn C, Brodeur GM, Reynolds CP, Seeger RC, Lottspeich F, Strahler JR, Hanash SM. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest 1991;88:341-5.
30. Chang CL, Zhu XX, Thoraval DH, Ungar D, Rawwas J, Hora N, Strahler JR, Hanash SM, Radany E. Nm23-H1 mutation in neuroblastoma [letter]. Nature 1994;370:335-6.
31. Leone A, Seeger RC, Hong CM, Hu YY, Arboleda MJ, Brodeur GM, Stram D, Slamon DJ, Steeg PS. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene 1993;8:855-65.
32. Niitsu N, Okabe-Kado J, Okamoto M, Takagi T, Yoshida T, Aoki S, Hirano M, Honma Y. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood 2001;97:1202-10.
33. Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 1999;94:3541-50.
34. Ozeki Y, Takishima K, Mamiya G. Immunohistochemical analysis of nm23/NDP kinase expression in human lung adenocarcinoma: association with tumor progression in Clara cell type. Jpn J Cancer Res 1994;85:840-6.
35. Nakamori S, Ishikawa O, Ohhigashi H, Kameyama M, Furukawa H, Sasaki Y, Inaji H, Higashiyama M, Imaoka S, Iwanaga T, Funai H, Wada A, Kimura N. Expression of nucleoside diphosphate kinase/nm23 gene product in human pancreatic cancer: an association with lymph node metastasis and tumor invasion. Clin Exp Metastasis 1993;11:151-8.
36. Royds JA, Cross SS, Silcocks PB, Scholefield JH, Rees RC, Stephenson TJ. Nm23 'anti-metastatic' gene product expression in colorectal carcinoma. J Pathol 1994;172:261-6.
37. Lacombe ML, Milon L, Munier A, Mehus JG, Lambeth DO. The human Nm23/nucleoside diphosphate kinases. J Bioenerg Biomembr 2000;32:247-58.
38. Hewlett AR, Petersen OW, Steeg PS, Bissell MJ. A novel function for the nm23-H1 gene: overexpression in human breast carcinoma cells leads to the formation of basement membrane and growth arrest. J Natl Cancer Inst 1994;86:1838-44.
39. Gervasi F, D'Agnano I, Vossio S, Zupi G, Sacchi A, Lombardi D. nm23 influences proliferation and differentiation of PC12 cells in response to nerve growth factor. Cell Growth Differ 1996;7:1689-95.
40. Willems R, Van Bockstaele DR, Lardon F, Lenjou M, Nijs G, Snoeck HW, Berneman ZN, Slegers H. Decrease in nucleoside diphosphate kinase (NDPK/nm23) expression during hematopoietic maturation. J Biol Chem 1998;273:13663-8.
41. Aryee DN, Simonitsch I, Mosberger I, Kos K, Mann G, Schlogl E, Potschger U, Gadner H, Radaszkiewicz T, Kovar H. Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressiveness. Br J Cancer 1996;74:1693-8.
42. Yamashiro S, Urano T, Shiku H, Furukawa K. Alteration of nm23 gene expression during the induced differentiation of human leukemia cell lines. Oncogene 1994;9:2461-8.
43. Schneider J, Romero H, Ruiz R, Centeno MM, Rodriguez-Escudero FJ. nm23 expression in advanced and borderline ovarian carcinoma. Anticancer Res 1996;16(3A):1197-202.
44. Kaya H, Evans MF, Ekicioglu G, Tuzlali S, Kullu S, Foster C. Anti-metastasis gene expression and numerical chromosomal abnormalities of chromosomes 1 & 17 in serous tumours of the ovary. Eur J Gynaecol Oncol 2001;22:240-2.
45. Alaiya AA, Franzen B, Fujioka K, Moberger B, Schedvins K, Silfversvard C, Linder S, Auer G. Phenotypic analysis of ovarian carcinoma: polypeptide expression in benign, borderline and malignant tumors. Int J Cancer 1997;73:678-83.
46. Harlozinska A, Bar JK, Gerber J. Nm23 expression in tissue sections and tumor effusion cells of ovarian neoplasms. Int J Cancer 1996;69:415-19.
47. Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J, Rosen B, Minkin S, et al. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 2005;7:603-13.
48. Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G, Zaika A, Boltze C, Meyer F, Andersson L, Knuutila S, Miettinen M et al. Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 2004;53:235-40.
49. Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ. Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor. J Am Soc Nephrol 1998;9:1873-80.
50. Bai J, Brody JR, Kadkol SS, Pasternack GR. Tumor suppression and potentiation by manipulation of pp32 expression. Oncogene 2001;20:2153-60.
51. Brody JR, Kadkol SS, Mahmoud MA, Rebel JM, Pasternack GR. Identification of sequences required for inhibition of oncogene-mediated transformation by pp32. J Biol Chem 1999;274:20053-5.
52. Kadkol SS, Brody JR, Epstein JI, Kuhajda FP, Pasternack GR. Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer. Prostate 1998;34:231-7.
53. Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, Kofron J, Donnelly J, Burns D, Ng SC, Rosenberg S, Wang X. Distinctive roles of PHAP proteins and prothymosin-α in a death regulatory pathway. Science 2003;299:223-6.
54. Brody JR, Kadkol SS, Hauer MC, Rajaii F, Lee J, Pasternack GR. pp32 reduction induces differentiation of TSU-Pr1 cells. Am J Pathol 2004;164:273-83.
55. Kadkol SS, El Naga GA, Brody JR, Bai J, Gusev Y, Dooley WC, Pasternack GR. Expression of pp32 gene family members in breast cancer. Breast Cancer Res Treat 2001;68:65-73.
56. Chen TH, Brody JR, Romantsev FE, Yu JG, Kayler AE, Voneiff E, Kuhajda FP, Pasternack GR. Structure of pp32, an acidic nuclear protein which inhibits oncogene-induced formation of transformed foci. Mol Biol Cell 1996;7:2045-56.
57. Bobola MS, Blank A, Berger MS, Stevens BA, Silber JR. Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res 2001;7:3510-18.
58. Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 2004;3:679-86.
59. Herring CJ, West CM, Wilks DP, Davidson SE, Hunter RD, Berry P, Forster G, MacKinnon J, Rafferty JA, Elder RH, Hendry JH, Margison GP. Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers. Br J Cancer 1998;78:1128-33.
60. Robertson KA, Bullock HA, Xu Y, Tritt R, Zimmerman E, Ulbright TM, Foster RS, Einhorn LH, Kelley MR. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res 2001;61:2220-5.
61. Schneider J, Pollan M, Jimenez E, Marenbach K, Martinez N, Volm M, Marx D, Meden H. nm23-H1 expression defines a high-risk subpopulation of patients with early-stage epithelial ovarian carcinoma. Br J Cancer 2000;82:1662-70.
62. Srivatsa PJ, Cliby WA, Keeney GL, Dodson MK, Suman VJ, Roche PC, Podratz KC. Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma. Gynecol Oncol 1996;60:363-72.
63. Tas F, Tuzlali S, Aydiner A, Saip P, Salihoglu Y, Iplikci A, Topuz E. Prognostic role of nm23 gene expression in patients with ovarian cancer. Am J Clin Oncol 2002;25:164-7.
64. Scambia G, Ferrandina G, Marone M, Benedetti Panici P, Giannitelli C, Piantelli M, Leone A, Mancuso S. nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters. J Clin Oncol 1996;14:334-42.
65. Baekelandt M, Holm R, Trope CG, Nesland JM, Kristensen GB. The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer. Ann Oncol 1999;10:1335-41.
66. Leary JA, Kerr J, Chenevix-Trench G, Doris CP, Hurst T, Houghton CR, Friedlander ML. Increased expression of the NME1 gene is associated with metastasis in epithelial ovarian cancer. Int J Cancer 1995;64:189-95.
67. Sak SC, Hamden P, Johnston CF, Paul AB, Kiltie AE. APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res 2005;11:6205-11.